Insights

Strategic Partnerships Valerio Therapeutics is actively pursuing co-development, out-licensing, and R&D collaborations to maximize its pipeline, presenting multiple in-road opportunities for strategic partnerships with biopharma companies seeking novel oncology and precision therapy assets.

Acquisition & Expansion Recent acquisitions and leadership changes signal aggressive growth and pipeline expansion, creating sales opportunities with potential vendors, service providers, and collaborators who can support post-merger integration, manufacturing scale, or battle-tested clinical development capabilities.

Tech Platform The proprietary V-Body ultra-small sdAb platform and advanced target identification models present a compelling selling point for contract development and manufacturing organizations (CDMOs), academic collaborations, and biotechs seeking high specificity, tissue penetration, and novel payload conjugation capabilities.

Clinical Focus Focus on indications with high unmet medical need and rapid translation from preclinical to clinical proof of concept offers opportunities to engage CROs, data analytics partners, and regulatory affairs consultants aligned with accelerated timelines and milestone-driven engagements.

Global Growth Euronext Growth presence, international partnerships, and agreements with science parks and accelerators indicate a readiness for international collaboration and service offerings across discovery, preclinical, and early clinical development, suggesting targeted outreach to global biotech hubs and funding networks.

Similar companies to Valerio Therapeutics

Valerio Therapeutics Tech Stack

Valerio Therapeutics uses 8 technology products and services including Burst Statistics, WordPress, Cloudflare, and more. Explore Valerio Therapeutics's tech stack below.

  • Burst Statistics
    Analytics
  • WordPress
    Content Management System
  • Cloudflare
    Content Management System
  • RSS
    Content Management System
  • MySQL
    Database
  • Element UI
    Javascript Frameworks
  • Underscore.js
    Javascript Libraries
  • GoDaddy
    Web Hosting

Media & News

Valerio Therapeutics's Email Address Formats

Valerio Therapeutics uses at least 2 format(s):
Valerio Therapeutics Email FormatsExamplePercentage
F.Last@onxeo.comJ.Doe@onxeo.com
86%
First.Last@onxeo.comJohn.Doe@onxeo.com
9%
Last@onxeo.comDoe@onxeo.com
5%
F.Last@valeriotx.comJ.Doe@valeriotx.com
100%

Frequently Asked Questions

What is Valerio Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact Valerio Therapeutics's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Valerio Therapeutics's stock symbol?

Minus sign iconPlus sign icon
Valerio Therapeutics is a publicly traded company; the company's stock symbol is ONXEO.CO.

What is Valerio Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Valerio Therapeutics's official website is valeriotx.com and has social profiles on LinkedIn.

What is Valerio Therapeutics's NAICS code?

Minus sign iconPlus sign icon
Valerio Therapeutics's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Valerio Therapeutics have currently?

Minus sign iconPlus sign icon
As of July 2026, Valerio Therapeutics has approximately 52 employees across 3 continents, including EuropeNorth AmericaSouth America. Key team members include Ceo: D. C.Chief Technology Officer: W. J.Chief Medical Officer: O. D. B.. Explore Valerio Therapeutics's employee directory with LeadIQ.

What industry does Valerio Therapeutics belong to?

Minus sign iconPlus sign icon
Valerio Therapeutics operates in the Pharmaceutical Manufacturing industry.

What technology does Valerio Therapeutics use?

Minus sign iconPlus sign icon
Valerio Therapeutics's tech stack includes Burst StatisticsWordPressCloudflareRSSMySQLElement UIUnderscore.jsGoDaddy.

What is Valerio Therapeutics's email format?

Minus sign iconPlus sign icon
Valerio Therapeutics's email format typically follows the pattern of F.Last@onxeo.com. Find more Valerio Therapeutics email formats with LeadIQ.

When was Valerio Therapeutics founded?

Minus sign iconPlus sign icon
Valerio Therapeutics was founded in 2014.
Valerio Therapeutics logo

Valerio Therapeutics

Pharmaceutical ManufacturingÎle-de-France, France51-200 Employees

Valerio Therapeutics is a Paris-based company advancing precision therapies for complex, underserved diseases. It operates an ultra-small antibody-based platform built on synthetic libraries derived from human antibody sequences, engineered to achieve deeper tissue penetration and highly targeted delivery. The company integrates predictive target identification, antibody optimization for specificity and affinity, and drug-conjugate development to advance candidates from preclinical research toward clinical proof of concept in areas with high unmet medical needs.

Valerio pursues collaborations through co-development, licensing, and research partnerships to maximize the potential of its programs. Recent milestones include the 2024 acquisition of Emglev Therapeutics and the 2026 appointment of a new chief executive officer, signaling ongoing corporate development. Based in Paris, Île-de-France, the company is a mid-sized player within the pharmaceutical manufacturing sector.

Section iconCompany Overview

Phone number
Stock Symbol
ONXEO.CO
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2014
Employees
51-200

Section iconFunding & Financials

  • $1M$10M

    Valerio Therapeutics's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1M$10M

    Valerio Therapeutics's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.